Core Viewpoint - A class action has been filed against Rocket Lab USA, Inc. for allegedly misleading investors regarding its business prospects during a specific period [1][2]. Allegations - The complaint alleges that Rocket Lab failed to disclose significant delays in its plans for three barge landing tests [2]. - A critical potable water issue was not scheduled to be resolved until January 2026, which impacted the launch pad preparation [2]. - Due to these issues, there was a substantial risk that Rocket Lab's Neutron rocket would not launch as planned in mid-2025 [2]. - The only contract for the Neutron rocket was made at a discount with an unreliable partner [2]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially misleading [2]. Stock Price Impact - Following the revelation of these issues on February 25, 2025, Rocket Lab's stock price dropped by $2.21, or 9.8%, closing at $20.28 per share [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by April 28, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Company Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Manhattan Associates, Inc. for allegedly misleading investors about its growth potential and revenue forecasts during a specified period [1][2]. Summary by Sections Allegations - The complaint claims that during the class period, Manhattan Associates provided investors with optimistic information regarding its expected revenue for fiscal year 2025, including confidence in forecasting despite macroeconomic challenges and the growth potential of its professional services [2]. - It is alleged that the company failed to disclose its actual capability to deliver responsible growth targets, suggesting that either the company was not equipped to meet these targets or its services were inadequate [2]. Financial Results and Stock Impact - On January 28, 2024, Manhattan Associates released its financial results for Q4 and the full fiscal year 2024, along with a reduced revenue guidance for fiscal year 2025, attributing this to a shift in professional services work and reduced customization [3]. - Following this announcement, the stock price fell from $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, marking a decline of over 24% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Manhattan Associates, with a deadline to file as lead plaintiff by April 28, 2025 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development a ...

Core Viewpoint - A class action lawsuit has been filed against Fluence Energy, Inc. for alleged violations of securities laws during the Class Period from October 28, 2021, to February 10, 2025, claiming that the company made misleading statements regarding its business and financial condition [1][3]. Company Overview - Fluence Energy, Inc. is a global provider of battery-based energy storage products and services, as well as AI-enabled digital applications for renewable energy storage. It operates as a holding company through Fluence Energy, LLC, which was established in 2018 as a joint venture between AES and Siemens [2]. Allegations in the Lawsuit - The lawsuit alleges that Fluence made false or misleading statements by failing to disclose significant issues, including: - Defective design and operational issues with a material portion of its energy storage products [3]. - Inadequate responses to known product defects and installation errors, along with unfulfilled warranty obligations [3]. - Overstated efficacy and safety of its energy storage products and the ability to deliver projects satisfactorily [3]. - Resulting inflated financial metrics, including adjusted EBITDA and gross profit margins [3]. - Exposure to undisclosed risks of reputational and financial harm due to these issues [3]. Impact on Stock Price - Following the revelation of these deficiencies, Fluence's stock price plummeted over 80%, dropping from highs of more than $39 per share to approximately $6 per share by the end of the Class Period [4]. Next Steps for Investors - Investors who purchased Fluence Class A stock during the Class Period have until May 12, 2025, to apply to serve as lead plaintiff in the class action [5].

Core Viewpoint - A class action lawsuit has been filed against Bakkt Holdings, Inc. for allegedly misleading investors about the stability and diversity of its crypto services revenue, particularly its reliance on a single contract with Webull [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Bakkt misrepresented the stability and diversity of its crypto services revenue and failed to disclose its substantial dependence on a single contract with Webull [2]. - Bakkt disclosed that Webull accounted for 74% of its crypto services revenue for the nine months ending September 30, 2024, and that 98% of its total revenue came from crypto services during the same period [3]. - Following the announcement of Webull's termination of their commercial agreement, Bakkt is expected to face a 73% loss in top-line revenue, leading to a significant drop in share price by $3.50 or 27.3% to close at $9.33 per share on March 18, 2025 [3]. Group 2: Legal Proceedings and Participation - Shareholders are encouraged to participate in the class action against Bakkt Holdings, with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no fees or expenses for representation [5].

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Everus Construction Group, Inc. ("Everus") (NYSE: ECG) common stock between October 31, 2024 and February 11, 2025, including investors who held MDU Resources Group, Inc. ("MDU Resources") common stock as of October 21, 2024 and acquired Everus common stock issued in connection with the spinoff of Everus Construction on or about Octob ...

Core Viewpoint - A class action has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of the Securities Exchange Act of 1934 related to misleading investors during a secondary stock offering and subsequent merger announcement [1][2][3]. Group 1: Allegations and Impact - The complaint claims that Cerevel's secondary offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger was announced [2]. - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [2]. - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders do not need to participate actively in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Everus Construction Group, Inc. for allegedly misleading investors about its backlog conversion cycle, which has negatively impacted revenue recognition [1][2]. Group 1: Class Action Details - The class action is on behalf of individuals and entities that purchased Everus common stock between October 31, 2024, and February 11, 2025, including those who held MDU Resources stock and acquired Everus shares during its spinoff [1]. - The lawsuit alleges that Everus failed to disclose that its backlog conversion cycle had elongated due to larger, more complex projects, leading to delayed revenue recognition [2]. - Following the release of its fourth quarter and full year 2024 financial results on February 11, 2025, Everus's stock price dropped by $18.88, or 27.6%, closing at $49.54 per share on February 13, 2025 [2]. Group 2: Participation and Representation - Shareholders interested in serving as lead plaintiffs in the class action are encouraged to contact Robbins LLP, which represents the class on a contingency fee basis, meaning no fees or expenses are required from shareholders [3][4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery if the class action settles [3].

Core Points - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System [1][2] - The complaint states that competition negatively impacted the demand and utilization of the Lapiplasty system, leading to a decline in Treace Medical's revenue [2] - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Company Overview - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1] - The company is under scrutiny for its failure to disclose critical information regarding competition and product demand [2] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 10, 2025 [3] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members [3] Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against The Trade Desk, Inc. for allegedly misleading investors about its business prospects during a specific period [1][2]. Group 1: Allegations and Challenges - The lawsuit claims that The Trade Desk failed to disclose significant execution challenges related to the rollout of its new platform, Kokai, which affected client transitions from the older platform, Solimar [2]. - These execution challenges reportedly delayed the Kokai rollout and negatively impacted the company's business operations and revenue growth [2]. - The positive statements made by the company regarding its business and prospects were deemed materially false and misleading due to these undisclosed issues [2]. Group 2: Financial Performance - On February 12, 2025, The Trade Desk reported fourth quarter revenue of $741 million, which was below its guidance of $756 million and analysts' expectations of $759.8 million [3]. - The company's revenue guidance for the first quarter of 2025 was at least $575 million, missing analysts' estimates of $581.5 million [3]. - Following the announcement of these results and the acknowledgment of the slower Kokai rollout, the stock price dropped by $40.31, or over 32%, from $122.23 to $81.92 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file their papers by April 21, 2025, to serve as lead plaintiffs [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].